Saturday 17 October 2026
Export CDIO’s income statement to Excel — free account
Cardio Diagnostics Holdings, Inc.
CDIO Healthcare Biotechnology
Cardio Diagnostics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14,800.00, down 57.6% from fiscal 2024. In the quarter to June 2026, revenue fell 28.0%, EPS grew 47.4% and free cash flow grew 15.6%, each against the same quarter a year earlier.
1.69
0.07
−3.98%
Follow CDIO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 23.91 | 5.13 | 5.70 | 2.42 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 307.50 | 255.00 | 106.80 | 30.60 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 1 | 8 | 9 | 15 | 17 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | ||||
| Gross margin, % | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | — | (1) | (5) | (8) | (8) | (6) | |||||
| EBT margin, % | — | — | — | — | — | (68,933.33) | (466,100.00) | (48,987.13) | (24,021.49) | (43,906.76) | |||||
| Net income | — | 0 | — | — | — | (1) | (5) | (8) | (8) | (6) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.02 | 0.01 | 0.04 | 0.04 | 0.01 | ||||
| Earnings | — | — | — | — | — | (16.02) | (45.34) | (19.82) | (9.31) | (3.71) | |||||
| Cash flow | — | — | — | — | — | (15.12) | (49.52) | (13.43) | (5.57) | (3.27) | |||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | (1.36) | (0.24) | (0.11) | |||||
| Free cash flow | — | — | — | — | — | (15.12) | (49.52) | (14.79) | (5.81) | (3.38) | |||||
| Book value | — | — | — | — | — | 27.60 | 41.85 | 7.00 | 10.67 | 3.98 | |||||
| Shares, m | — | — | — | — | — | 0 | 0 | 0 | 1 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 706.27 | 318.47 | |||||
| P/B | — | — | — | — | — | 3,506.12 | 0.79 | 13.11 | 2.58 | 0.68 | |||||
| EV/Sales | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 481.99 | (24.52) | |||||
| EV/FCF | — | — | — | — | — | 0.00 | 0.14 | (6.00) | (3.23) | 0.06 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (5) | (6) | (5) | (6) | ||||
| Capex | — | — | — | — | — | 0 | 0 | (1) | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | (1) | (5) | (6) | (5) | (6) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 1 | 4 | 2 | 8 | 5 | ||||
| Total debt | — | — | — | — | — | — | 1 | — | — | — | |||||
| Net debt | — | — | — | — | — | (1) | (4) | (1) | (8) | (5) | |||||
| Shareholders’ equity | — | — | — | — | — | 1 | 4 | 3 | 10 | 7 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (112.60) | (126.80) | (156.40) | (111.20) | (70.70) | ||||
| ROIC | — | — | — | — | — | (69.83) | (1,543.33) | (270.31) | (302.18) | (217.55) | |||||
| ROE | — | — | — | — | — | 0.00 | (173.60) | (230.77) | (133.97) | (78.62) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Cardio Diagnostics Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ORGS Orgenesis Inc. | $5.7M | — (loss-making) | 1.0× | +82.42% (above 0%: growing) | n/m | −317.93% (below 0%: shrinking) | 2,780.73% | (6,044.52%) | Compare |
| CANF Can-Fite Biopharma Ltd | $5.6M | — (loss-making) | — (loss-making) | −1.18% (below 0%: shrinking) | n/m | +12.63% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BGMS Bio Green Med Solution, Inc. | $5.5M | — (loss-making) | — (loss-making) | +3,260.00% (above 0%: growing) | n/m | +66.67% (above 0%: growing) | 23.51% | (124.40%) | Compare |
| CELZ Creative Medical Technology Holdings, Inc. | $5.4M | — (loss-making) | — (loss-making) | 0.00% | n/m | −27.05% (below 0%: shrinking) | 66.67% | 0.00% | Compare |
| CDIO Cardio Diagnostics Holdings, Inc. | $5.2M | — (loss-making) | — (loss-making) | −28.00% (below 0%: shrinking) | n/m | +15.58% (above 0%: growing) | 100.00% | (27,742.59%) | |
| PULM Pulmatrix, Inc. | $5.2M | — (loss-making) | — (loss-making) | −99.86% (below 0%: shrinking) | n/m | +41.26% (above 0%: growing) | 100.00% | 0.00% | Compare |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $5.0M | — (loss-making) | — | — | n/m | +57.80% (above 0%: growing) | — | 0.00% | Compare |
| LGVN Longeveron Inc. | $4.8M | — (loss-making) | — (loss-making) | −9.18% (below 0%: shrinking) | n/m | −49.12% (below 0%: shrinking) | 63.41% | (2,150.17%) | Compare |
| XBIO Xenetic Biosciences, Inc. | $4.7M | — (loss-making) | — (loss-making) | +11.99% (above 0%: growing) | n/m | −128.11% (below 0%: shrinking) | 100.00% | (147.09%) | Compare |
| Median of peers | $5.3M | — | — | 0.00% | — | −7.21% | 66.67% | (62.20%) |
Cardio Diagnostics Holdings, Inc. (CDIO) key facts
- Concern: Cardio Diagnostics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14,800.00, down 57.6% from fiscal 2024.
- Cardio Diagnostics Holdings, Inc. (CDIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CDIO traded at $1.69, a market capitalization of $5.2 million.
- Return on equity was −78.6% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −3.61 (distress zone) for fiscal 2025.